Plain-English translation of NCT07011745 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer's Disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing KarXT + KarX-EC, a new medication combination designed to reduce agitation and aggressive behaviors in people living with Alzheimer's disease. About half of participants will receive the medication while the other half receive a placebo (inactive pill), and researchers will compare how well each group improves. The study involves 426 people and is run by Bristol-Myers Squibb.
Agitation and aggression are common and distressing symptoms in Alzheimer's disease, but there are few safe treatment options available. Researchers hope this medication will help calm these behaviors without serious side effects.
You likely qualify if…
You likely don't qualify if…
You would attend multiple study visits over several weeks or months. At each visit, your caregiver would help report on your agitation symptoms, and researchers would assess how you are doing using standardized questionnaires. You would take either the new medication or a placebo daily, and your caregiver would help ensure you take it as directed. Throughout the study, the team will monitor your safety and measure whether the medication reduces your agitation compared to placebo.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States